Where to Buy a THC Analyzer
Kelly Weimert
October 17th, 2017
News
Interplay of graphic analyzer bars, music notes, lights and abstract design elements on the subject of music, concert performance, sound and entertainment
With cannabis becoming increasingly legal and accessible throughout the country, we’ve come a long way from having to guess at the potency of the flower in our hands.
No longer is cannabis only coming from strange and uncertain sources, leaving the consumer unsure as to what, exactly, they’re consuming. Thanks to marijuana’s increased legality, lawful consumers are treated to a more standardized drug as growers, cultivators, distributors, and retailers become more diligent about what, exactly, they’re growing and how they’re doing it. And, fortunately for all of us, technology is making it even easier for that analysis to take place. Even from the comfort of your own home.
A number of tech companies are putting out products designed to analyze the contents of cannabis (AKA the percentage of different cannabinoids in the plant), often called THC analyzers. Up until somewhat recently, though, you’d have to be willing to fork over thousands of dollars to a lab if you wanted to assess your cannabis’ contents. But it looks like the tides are turning on that front as more affordable devices begin to make their way to the market.
The MyDx analyzer is is a smart handheld device that uses technology developed by NASA’s Jet Propulsion Lab to analyze the levels of THC, CBD, CBN, THCa, and CBDa cannabinoids in a flower, in addition to more than 20 terpenes. And what sets it apart from other methods of testing is that it’s relatively affordable and designed to be used by the average consumer from their home.
The MyDx package costs $699, which includes the analyzer itself, a replaceable cannabis-specific sensor, and a smartphone app to help you manage it all.
The handheld device works by accepting a small sample of the flower in question into a port and, three and a half minutes later, it delivers the results of a chemical analysis of the plant right to your phone.
The results of any given analysis will show you the chemical profile of the plant, the strains it resembles, how it’s likely to make you feel, and the medical symptoms it might alleviate. Additionally, it allows you to track how the plant made you feel as an individual, so you’ll have a better idea of what chemical makeup is best in line with the ailments you’re looking to manage. It also makes it easy to print or share that profile on social media for easy reference later.
Even better, the analyzer doesn’t stop at chemical profiles. It can also detect pesticides, heavy metals, and other potentially harmful impurities in the flower so that consumers can feel more confident that what they’re ingesting is safe.
And in addition to all of those cannabis benefits, the MyDx is equipped to a host a series of different removable sensors that can analyze the content of air, water, and organic matter outside of cannabis. For instance, the air sensor, called AeroDx, can make the lives of growers a whole lot easier by detecting temperature, humidity, and carbon dioxide content in the air, making the entire growing process easier and more efficient.
There are, however, a few drawbacks of the device. For one thing, while it can tell you with reasonable accuracy the chemical profile of the flower, it can’t tell you the precise strain. Arguably, though, the name of the strain is far less consequential and therefore less important overall than the actual makeup of the plant.
Another negative of the device is that it’s not very effective when it comes to detecting cannabidiol (CBD) — a common cannabinoid used to relieve myriad illnesses such as anxiety and insomnia. Currently, the sensor is unable to detect more than 1 percent of CBD in any given sample. Even if the amount of CBD is higher than 1 percent, the results reading will still max out at that number, which means it’s not going to be very helpful for folks who rely on CBD to manage ailments.
The device is also lacking a bit in the accuracy department. As it stands, it isn’t more accurate than a comprehensive lab test. “We sacrifice accuracy for simplicity and ease of use to consumers. The labs will typically always be more accurate than handheld secondary tools,” said the founder and CEO of the company, Daniel Yazbeck. But for the everyday consumer looking to gain insight into their plant, it can be considered reasonably accurate.
Right now, MyDx doesn’t have much in the way of viable competitors. While it’s true that there are a number of lab tests and devices, like the Cannalyzer-420, designed to analyze the chemical compounds in the plant, none of these options come close to being affordable for the average, at-home consumer. The Cannalyzer-420, for instance, can only be rented and it costs a whopping $420 per week to rent.
Bottom Line
If you’re looking for a simple, in-home cannabis analyzer, it’ll cost you about $700 and a bit of accuracy, but if you’re someone who regularly manages ailments with the flower, it’s a worthy investment to consider.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Kelly Weimert
Kelly is a full-time freelance writer based in Austin, TX. A happy hybrid of geek and hippie, when she's not nestled into her couch crankin' out crafty prose with her miscreant Chihuahua, you can find her frolicking outside to keep her sanity in check.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Zenabis owns 660,000 square feet of high quality indoor facility space, as well as 2.1 million square feet of greenhouse space that will be dedicated to cannabis production once fully built-out.
Harborside Inc. (CSE: HBOR) is one of the oldest, largest and most respected cannabis retailers in the world with award-winning flower, concentrates, edibles and other cannabis products from California’s most respected growers and manufacturers.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
